COLLEGIUM PHARMACEUTICAL Reports Third Quarter Earnings for Fiscal Year 2023
November 20, 2023
🌥️Earnings Overview
COLLEGIUM PHARMACEUTICAL ($NASDAQ:COLL) reported total revenue of USD 136.7 million for the third quarter of fiscal year 2023, up 7.6% from the same period in the prior year. Net income for the quarter ending September 30 2023 was USD 20.6 million, a substantial improvement from the net income of 0.5 million in the same quarter in the previous year.
Share Price
However, by the end of the day, the stock closed at $21.7, which was a decrease of 1.9% from its previous closing price of $22.1. The financials for the quarter indicated that COLLEGIUM PHARMACEUTICAL had a strong performance, with revenue increasing by 11% over the prior year period. The company attributed its success to its focus on innovative treatments for unmet medical needs and its continued investment in research and development.
Additionally, COLLEGIUM PHARMACEUTICAL also saw growth from its pipeline of products in development. The company’s CEO cited their commitment to patient care and pursuing groundbreaking treatments as key reasons for the company’s strong performance. The company is confident that it will continue to drive innovation and achieve success in its mission to expand access to reliable and effective medications. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Collegium Pharmaceutical. More…
| Total Revenues | Net Income | Net Margin |
| 546.64 | 9.02 | 5.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Collegium Pharmaceutical. More…
| Operations | Investing | Financing |
| 267.74 | -46.66 | -98.17 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Collegium Pharmaceutical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.18k | 998.71 | 5.49 |
Key Ratios Snapshot
Some of the financial key ratios for Collegium Pharmaceutical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 21.1% | 44.4% | 19.4% |
| FCF Margin | ROE | ROA |
| 48.8% | 34.9% | 5.6% |
Analysis
At GoodWhale, we have taken a close look at the financials of COLLEGIUM PHARMACEUTICAL. According to our Star Chart, COLLEGIUM PHARMACEUTICAL has an intermediate health score of 6/10, considering its cashflows and debt. This indicates that it might be able to pay off debt and fund future operations. Moreover, we have classified COLLEGIUM PHARMACEUTICAL as a ‘gorilla’, meaning that it has achieved stable and high revenue or earning growth due to its strong competitive advantage. Therefore, this may be of interest to investors who are looking for growth opportunities and companies with a strong competitive edge. Overall, our analysis indicates that COLLEGIUM PHARMACEUTICAL is strong in growth, profitability, and weak in terms of asset and dividend. Thus, investors may want to consider these factors when evaluating their investment options. More…
Peers
The company’s competitors include Medexus Pharmaceuticals Inc, PLx Pharma Inc, and CURE Pharmaceutical Holding Corp.
– Medexus Pharmaceuticals Inc ($TSX:MDP)
Medexus Pharmaceuticals Inc is a Canadian-based specialty pharmaceutical company with a focus on hematology and immunology. The company has a market capitalization of 48.29M as of 2022 and a return on equity of 48.45%. Medexus is dedicated to improving the lives of patients by developing and commercializing innovative therapies. The company’s products include IXIFI (ifosfamide), IMMU-132 (rafamycin SV), RYANODEX (dantrolene sodium), and AMG420 (cannabidiol). Medexus is headquartered in Mississauga, Ontario, Canada.
– PLx Pharma Inc ($NASDAQ:PLXP)
PLC Pharma Inc is a pharmaceutical company with a market cap of 17.48M and a ROE of -106.47%. The company focuses on the development and commercialization of drugs for the treatment of severe and life-threatening conditions.
– CURE Pharmaceutical Holding Corp ($OTCPK:CURR)
CURE Pharmaceutical Holding Corp is a pharmaceutical company that develops and manufactures oral and topical drugs, as well as transdermal patches. The company has a market cap of 14.16M as of 2022 and a return on equity of -150.91%. The company’s products are designed to treat a variety of conditions, including pain, inflammation, and skin conditions.
Summary
COLLEGIUM PHARMACEUTICAL released its earnings results for the third quarter of 2023 which showed a 7.6% increase in total revenue to USD 136.7 million. Net income for the quarter increased significantly from last year’s USD 0.5 million to USD 20.6 million. This is an encouraging sign for potential investors, suggesting that the company is continuing to grow and achieve consistent profits. Investors should consider COLLEGIUM PHARMACEUTICAL as a potential long-term investment as it has consistently shown strong performance and stability.
Related Posts
Recent Posts
